EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid‐positive early Alzheimer's disease

Viswanath Devanarayan iD, Arnaud Charil, Kanta Horie, Thomas Doherty, Daniel A Llano, Erica Andreozzi, Pallavi Sachdev, Yuanqing Ye, Leema Krishna Murali, Jin Zhou, Larisa Reyderman, Harald Hampel iD und 4 weitere

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.14411 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Viswanath Devanarayan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Evidence Generation, Eisai Inc., Nutley, New Jersey, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Brain, tau Proteins. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, Eisai Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND This study examines whether phosphorylated plasma Tau217 ratio (pTau217R) can predict tau accumulation in different brain regions, as measured by positron emission tomography (PET) standardized uptake value ratio (SUVR), for staging Alzheimer's disease (AD). METHODS Plasma pTau217R was measured using immunoprecipitation‐mass spectrometry. Models for predicting tau PET SUVR, developed with 144 early AD individuals using [ 18 F]MK6240, were validated in two validation sets, VS1 (98 early AD) and VS2 (47 preclinical/early AD with a different tracer, flortaucipir (Tauvid)), all amyloid‐beta positive (Aβ+). RESULTS The pTau217R‐based model predicted tau levels up to an SUVR of 2 in multiple brain regions, effectively assessing tau status at different tau levels with receiver operating characteristic (ROC) curve areas of 0.84–0.95 in VS1 and 0.71–0.88 in VS2 (using a different tracer). It reduced PET scan needs by 65% while maintaining 95% sensitivity. DISCUSSION PTau217R reliably predicts regional tau accumulation in early AD, reducing reliance on tau PET scans and broadening its clinical application. CLINICAL TRIAL REGISTRATION NUMBER: NCT03887455 (ClarityAD) Highlights Developed a model using plasma pTau217R to predict tau levels across brain regions. pTau217R model outperformed models based on clinical, MRI, and other blood biomarkers. The model reliably predicted tau levels exceeding tau positivity and higher thresholds. Screening with pTau217R could reduce tau PET scans by 65% at 95% sensitivity. pTau217R model aids in disease staging and monitoring in early AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAmyloid beta-PeptidesBraintau ProteinsAgedAged, 80 and overFemaleHumansMaleMiddle AgedBiomarkersPhosphorylationPositron-Emission Tomography

Stichwörter der Autor:innen

Tau PETblood–based biomarkersdiagnosisdisease continuumdisease stagingpatient monitoringpatient screeningprediction

Substanzen

Amyloid beta-PeptidesBiomarkersMAPT protein, humantau Proteins

Autor:innen und Institutionen

  • Clinical Evidence Generation, Eisai Inc., Nutley, New Jersey, USA.
  • Department of Mathematics, Statistics and Computer Science, University of Illinois Chicago, Chicago, Illinois, USA.
  • The Tracy Family SILQ Center, Washington University School of Medicine, St Louis, Missouri, USA.
  • Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Clinical Evidence Generation, Eisai Ltd., Hatfield, UK.
  • Biomedical and Translational Sciences, Carle Illinois College of Medicine, Urbana, Illinois, USA.

ORCID-Profile: Viswanath Devanarayan, Harald Hampel

Förderung

  • NIA NIH HHS
  • Eisai Inc

Zitieren

APA

Devanarayan, V., Charil, A., Horie, K., Doherty, T., Llano, D. A., Andreozzi, E., Sachdev, P., Ye, Y., Murali, L. K., Zhou, J., Reyderman, L., Hampel, H., Kramer, L. D., Dhadda, S., Irizarry, M. C., & Alzheimer's Disease Neuroimaging Initiative (ADNI) (2025). Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid‐positive early Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14411

Vancouver

Devanarayan V, Charil A, Horie K, Doherty T, Llano DA, Andreozzi E, et al. Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid‐positive early Alzheimer's disease. Alzheimer's & Dementia. 2025. doi:10.1002/alz.14411

BibTeX
@article{Devanarayan2025,
  author = {Devanarayan, Viswanath and Charil, Arnaud and Horie, Kanta and Doherty, Thomas and Llano, Daniel A and Andreozzi, Erica and Sachdev, Pallavi and Ye, Yuanqing and Murali, Leema Krishna and Zhou, Jin and Reyderman, Larisa and Hampel, Harald and Kramer, Lynn D and Dhadda, Shobha and Irizarry, Michael C and Alzheimer's Disease Neuroimaging Initiative (ADNI), Alzheimer's Disease Neuroimaging Initiative (ADNI)},
  title = {Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid‐positive early Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.14411}
}
Kostenlos starten →